TYP — Tryptamine Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- AU$9.67m
- AU$7.06m
- AU$3.41m
- 15
- 11
- 80
- 29
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.029 | 2.73 | 4.2 | 4.21 | 3.41 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2.31 | 8 | 12.7 | 14.3 | 10.5 |
Operating Profit | -2.28 | -5.28 | -8.47 | -10.1 | -7.13 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.28 | -5.28 | -8.47 | -10.1 | -7.13 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.28 | -5.28 | -8.47 | -10.1 | -7.13 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.28 | -5.28 | -8.47 | -10.1 | -7.13 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.28 | -5.28 | -8.47 | -10.1 | -7.13 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.036 | -0.05 | -0.057 | -0.057 | -0.036 |